MX2014002171A - Tratamientos de combinacion para hepatitis c. - Google Patents

Tratamientos de combinacion para hepatitis c.

Info

Publication number
MX2014002171A
MX2014002171A MX2014002171A MX2014002171A MX2014002171A MX 2014002171 A MX2014002171 A MX 2014002171A MX 2014002171 A MX2014002171 A MX 2014002171A MX 2014002171 A MX2014002171 A MX 2014002171A MX 2014002171 A MX2014002171 A MX 2014002171A
Authority
MX
Mexico
Prior art keywords
hepatitis
combination treatments
combination
administering
iii
Prior art date
Application number
MX2014002171A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2014002171A publication Critical patent/MX2014002171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona métodos y composiciones farmacéuticas para el tratamiento de Hepatitis C en un ser humano que lo necesite, los cuales comprenden administrar un compuesto de la fórmula (I), (II), (III), (IV), (V), o (VI) descrito en la presente, o una sal farmacéuticamente aceptable del mismo, en combinación con uno o más agentes terapéuticos adicionales para Hepatitis C.
MX2014002171A 2011-08-24 2012-08-24 Tratamientos de combinacion para hepatitis c. MX2014002171A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US201261617813P 2012-03-30 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Publications (1)

Publication Number Publication Date
MX2014002171A true MX2014002171A (es) 2014-04-25

Family

ID=47746891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002171A MX2014002171A (es) 2011-08-24 2012-08-24 Tratamientos de combinacion para hepatitis c.

Country Status (17)

Country Link
US (1) US20140234253A1 (es)
EP (1) EP2747569A4 (es)
JP (2) JP2014527061A (es)
KR (1) KR20140065427A (es)
CN (1) CN103917095A (es)
AU (1) AU2012298750A1 (es)
BR (1) BR112014004182A2 (es)
CA (1) CA2845321A1 (es)
CL (1) CL2014000428A1 (es)
CO (1) CO6890100A2 (es)
CR (1) CR20140086A (es)
EA (1) EA201490254A1 (es)
HK (1) HK1198869A1 (es)
IL (1) IL230844A0 (es)
MX (1) MX2014002171A (es)
SG (1) SG2014010490A (es)
WO (1) WO2013028953A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3006441A1 (en) * 2009-09-04 2016-04-13 Janssen Pharmaceuticals, Inc. Ns5a inhibitors
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
DE202012012954U1 (de) 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2984098A2 (en) 2013-04-12 2016-02-17 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
WO2015096674A1 (zh) * 2013-12-23 2015-07-02 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
WO2015101215A1 (zh) * 2013-12-31 2015-07-09 南京圣和药业股份有限公司 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用
WO2015109445A1 (zh) * 2014-01-21 2015-07-30 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
KR20170083108A (ko) * 2014-11-10 2017-07-17 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 장기 작용 약학적 조성물
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TW202042807A (zh) * 2009-05-13 2020-12-01 美商基利法瑪席特有限責任公司 抗病毒化合物
EP3006441A1 (en) * 2009-09-04 2016-04-13 Janssen Pharmaceuticals, Inc. Ns5a inhibitors
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010330862B2 (en) * 2009-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
US20140234253A1 (en) 2014-08-21
JP2014527061A (ja) 2014-10-09
HK1198869A1 (en) 2015-06-19
EA201490254A1 (ru) 2014-07-30
AU2012298750A1 (en) 2014-03-13
CN103917095A (zh) 2014-07-09
SG2014010490A (en) 2014-04-28
CA2845321A1 (en) 2013-02-28
CO6890100A2 (es) 2014-03-10
CL2014000428A1 (es) 2014-08-01
IL230844A0 (en) 2014-03-31
CR20140086A (es) 2014-05-02
JP2017165746A (ja) 2017-09-21
BR112014004182A2 (pt) 2017-03-14
EP2747569A1 (en) 2014-07-02
EP2747569A4 (en) 2015-07-08
KR20140065427A (ko) 2014-05-29
WO2013028953A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12016502355B1 (en) Pharmaceutical composition
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2014003180A (es) Metodos para tratar vhc.
MX2013008012A (es) Tratamiento para la lipodistrofia.
PH12016502352A1 (en) Pharmaceutical composition
MX2015010829A (es) Compuestos terapeuticos y sus usos.
TW201613578A (en) Pharmaceutical combinations
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
EA201490199A8 (ru) Терапевтические способы
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
EA201070844A1 (ru) ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма